Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations-Reference-Cited by-同舟云学术

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations

Published:2021-09-13 Issue:16 Volume:81 Page:1382-1389
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Sokolova Alexandra O.¹^ORCID,Marshall Catherine H.²,Lozano Rebeca³⁴,Gulati Roman⁵^ORCID,Ledet Elisa M.⁶^ORCID,De Sarkar Navonil⁵,Grivas Petros⁵⁷,Higano Celestia S.⁵⁷,Montgomery Bruce⁷,Nelson Peter S.⁵⁷,Olmos David³⁴,Sokolov Vadim⁶,Schweizer Michael T.⁵⁷^ORCID,Yezefski Todd A.⁷,Yu Evan Y.⁵⁷,Paller Channing J.²^ORCID,Sartor Oliver⁸^ORCID,Castro Elena³⁴⁹,Antonarakis Emmanuel S.²^ORCID,Cheng Heather H.⁵⁷^ORCID

Affiliation:

1. Division of Medical Oncology Oregon Health Science University Portland Oregon USA

2. Division on Medical Oncology, Johns Hopkins School of Medicine Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland USA

3. Prostate Cancer Clinical Research Unit, Division on Medical Oncology Spanish National Cancer Research Centre (CNIO) Madrid Spain

4. Division on Medical Oncology, Genitourinary Cancer Traslational Research Group Instituto de Investigación Biomédica de Málaga Malaga Spain

5. Fred Hutchinson Cancer Research Center Seattle Washington USA

6. Systems Engineering and Operations Research Department George Mason University Fairfax Virginia USA

7. Division of Medical Oncology, Department of Medicine University of Washington Seattle Washington USA

8. Division on Medical Oncology Tulane University School of Medicine New Orleans Louisiana USA

9. Division on Medical Oncology Hospital Universitario Virgen de la Victoria y Regional de Málaga Málaga Spain

Funder

Center for Strategic Scientific Initiatives, National Cancer Institute

Prostate Cancer Foundation

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24236

Reference33 articles.

1. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

2. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

3. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

4. Germline and Somatic Mutations in Prostate Cancer for the Clinician

5. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of Genetic Mutations in Patients with Metastatic Prostate Cancer in a Cohort of Mexican Patients;Société Internationale d’Urologie Journal;2024-06-05

2. Germline and somatic mutations in prostate cancer: Implications for treatment;Current Problems in Cancer;2024-06

3. PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence;Clinical Genitourinary Cancer;2023-12

4. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis;European Urology Oncology;2023-09

5. Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes;Clinical Cancer Research;2023-05-01